Tag: Praxbind
Final Phase III results support safety of idarucizumab as reversal agent...
Final results from RE-VERSE AD study show that idarucizumab, marketed in the US as Praxbind (Boehringer Ingelheim), was able to immediately reverse the anticoagulant...
Boehringer Ingelheim launches RE-VECTO global programme to explore idarucizumab use in...
Boehringer Ingelheim has announced the launch of its global RE-VECTO programme for idarucizumab (Praxbind), the specific reversal agent for dabigatran etexilate (Pradaxa).
Idarucizumab is approved...